RBC Life Sciences Inc. reported unaudited consolidated earnings results for the full year ended December 31, 2012. For the period, the company reported net loss of $361,000 or $0.02 per basic and diluted share on Net Sales were $25,160,000 against net loss of $71,000 on Net Sales were $28,448,000a year ago. Operating loss was $464,000 compared to $71,000 a year ago.

Loss before income taxes was $590,000 compared to $211,000 a year ago. The net loss resulted primarily from lower operating margins as a result of the sales decline, as well as increased operating costs related to the first full year of branch office operations in Taiwan and higher product testing costs for compliance with GMP regulations.